MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (577)	2/19/2002 2:44:46 AM
From: Icebrg	Read Replies (2) of 2240

Sanofi-Synthelabo Exercises Its First Option for an Anti-Melanoma Cancer Vaccine in Its Partnership With Immuno-Designed Molecules (IDM) PARIS, Feb. 19 /PRNewswire/ -- Immuno-Designed Molecules, S.A. (IDM) and Sanofi-Synthelabo S.A. (Paris Bourse: Sicovam code 12057) announce today that Sanofi-Synthelabo is exercising its first option to develop and market IDM's Cell Drug(TM) known as IDD3 for the treatment of melanoma. Following the announcement of their partnership on 22 January 2002, Sanofi-Synthelabo and IDM agreed that this advanced program is particularly interesting to Sanofi-Synthelabo for the following reasons: * There is a very large un-met medical need in this indication. * This indication is likely to be responsive to an immuno-therapeutic treatment. * IDD3 has successfully completed initial Phase II trials with promising results. * The Cell Drug selected is a dendritic cell-based therapeutic vaccine using IL-13, a compound which Sanofi-Synthelabo discovered and which formed the basis of the first partnership between the two companies in 1999. Sanofi-Synthelabo's exercising of their option triggers the payment of milestones, the re-imbursement of clinical development costs previously incurred by IDM for this Cell Drug as well as the re-imbursement of the clinical development program as it moves forward. Jean-Loup Romet-Lemonne, MD, President and CEO of IDM stated: ``Sanofi-Synthelabo's first selection of one advanced Cell Drug in such a short period of time following the conclusion of our agreement clearly demonstrates its commitment to making a number of our Cell Drugs part of its therapeutic portfolio. At IDM we have already launched an organized program that should bring this Cell Drug to the marketplace in a competitive time-frame.'' IDM - The Immunogenics Company® IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer. Medarex holds 29 % of IDM's equity.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next